{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:12:44Z","timestamp":1788441164076,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115720","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:23:44Z","timestamp":1692339824000},"page":"115720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur"],"prefix":"10.1016","volume":"260","author":[{"given":"Koon Mook","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Sun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Duk","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meehyein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-2011","authenticated-orcid":false,"given":"Yong-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115720_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115720_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115720_bib3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115720_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115720_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejmech.2023.115720_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115720_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","article-title":"An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron","volume":"7","author":"Quan","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115720_bib8","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115720_bib9","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-020-19662-4","article-title":"Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115720_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115720_bib11","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115720_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01819-20","article-title":"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19","volume":"95","author":"De Vries","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115720_bib13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115720_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115720_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2023.115720_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115720_bib17","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115720_bib18","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115720_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115720_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc5332","article-title":"3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV\u2013infected mice","volume":"12","author":"Rathnayake","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2023.115720_bib21","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1021\/acscatal.0c03420","article-title":"Unraveling the SARS-CoV-2 main protease mechanism using multiscale methods","volume":"10","author":"Ramos-Guzm\u00e1n","year":"2020","journal-title":"ACS Catal."},{"key":"10.1016\/j.ejmech.2023.115720_bib22","series-title":"Hydrolytic Enzymes","author":"Brocklehurst","year":"1987"},{"key":"10.1016\/j.ejmech.2023.115720_bib23","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115720_bib24","doi-asserted-by":"crossref","first-page":"29940","DOI":"10.1039\/D2CP03681A","article-title":"Optimization of potential non-covalent inhibitors for the SARS-CoV-2 main protease inspected by a descriptor of the subpocket occupancy","volume":"24","author":"Sun","year":"2022","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejmech.2023.115720_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2023.115720_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acscentsci.1c00910","article-title":"Evaluation of SARS-CoV-2 main protease inhibitors using a novel cell-based assay","volume":"8","author":"Cao","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.115720_bib27","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.apsb.2021.10.026","article-title":"Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays","volume":"12","author":"Ma","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115720_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115720_bib29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jcc.10306","article-title":"Detailed analysis of grid\u2010based molecular docking: a case study of CDOCKER\u2014a CHARMm\u2010based MD docking algorithm","volume":"24","author":"Wu","year":"2003","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2023.115720_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115720_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.sbi.2004.03.009","article-title":"Recent advances in the development and application of implicit solvent models in biomolecule simulations","volume":"14","author":"Feig","year":"2004","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2023.115720_bib32","doi-asserted-by":"crossref","first-page":"8726","DOI":"10.1021\/jp020674r","article-title":"Introducing an implicit membrane in generalized Born\/solvent accessibility continuum solvent models","volume":"106","author":"Spassov","year":"2002","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2023.115720_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcc.540040211","article-title":"CHARMM: a program for macromolecular energy, minimization, and dynamics calculations","volume":"4","author":"Brooks","year":"1983","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2023.115720_bib34","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/bioinformatics\/btaa009","article-title":"The Protein Imager: a full-featured online molecular viewer interface with server-side HQ-rendering capabilities","volume":"36","author":"Tomasello","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2023.115720_bib35","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevB.45.13244","article-title":"Accurate and simple analytic representation of the electron-gas correlation energy","volume":"45","author":"Perdew","year":"1992","journal-title":"Phys. Rev. B"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:56:24Z","timestamp":1759330584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423006876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"alternative-id":["S0223523423006876"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115720","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115720"}}